Prostatype Genomics (PROGEN.ST) Stock Price
Prostatype Genomics Price
Revenue has compounded at 19.3% per year over the past 10 years to 594,000.00 SEK. Prostatype Genomics's net margin stands at -7,492.1%, up from -156,297.6% several years earlier.
Prostatype Genomics stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Prostatype Genomics business model & stock analysis
Frequently asked questions about Prostatype Genomics
Converted at the current exchange rate, the Prostatype Genomics share trades at 0.01 EUR (0.10 SEK).
The expected revenue of Prostatype Genomics is 12.63 M SEK. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Prostatype Genomics is -245.11 M SEK. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Prostatype Genomics is currently -0.02. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Prostatype Genomics stock.
The price-to-sales ratio (P/S) of Prostatype Genomics is currently 0.42. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Prostatype Genomics stock.
The Eulerpool Quality Score for Prostatype Genomics is 4/10.
The ISIN of Prostatype Genomics is SE0023261532. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Prostatype Genomics is A2QEC5. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Prostatype Genomics is PROGEN.ST. The ticker symbol is used to trade Prostatype Genomics shares on the stock exchange.
Prostatype Genomics stock
Prostatype Genomics Peer Group
All fundamentals and in-depth analysis of Prostatype Genomics
Our stock analysis for Prostatype Genomics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Prostatype Genomics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.